|1.||Cotter, Gad: 13 articles (05/2015 - 10/2008)|
|2.||Metra, Marco: 13 articles (05/2015 - 10/2008)|
|3.||Givertz, Michael M: 13 articles (05/2015 - 10/2007)|
|4.||Ponikowski, Piotr: 12 articles (05/2015 - 01/2010)|
|5.||O'Connor, Christopher M: 12 articles (05/2015 - 10/2008)|
|6.||Massie, Barry M: 12 articles (05/2015 - 10/2007)|
|7.||Dittrich, Howard C: 10 articles (05/2015 - 10/2007)|
|8.||Cleland, John G F: 9 articles (05/2015 - 08/2006)|
|9.||Teerlink, John R: 9 articles (05/2015 - 10/2010)|
|10.||Voors, Adriaan A: 8 articles (05/2015 - 05/2011)|
|1.||Acute Kidney Injury (Acute Renal Failure)
04/01/1994 - "Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in various models of acute renal failure in rats."
02/23/2001 - "KW-3902 may be especially beneficial in patients at high risk for developing acute renal failure following radiocontrast media application or in patients in which extracellular fluid volume expansion is limited by clinical conditions such as congestive heart failure."
01/01/1994 - "We investigated the possible renal protective effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a selective and potent adenosine A1-receptor antagonist, against cephaloridine (CER)-induced acute renal failure (ARF) in rats. "
04/01/1995 - "Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats."
06/01/1994 - "We investigated the possible renal protective effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), an adenosine A1-receptor antagonist, against gentamicin (GM)-induced acute renal failure (ARF) in rats. "
12/01/2009 - "Rolofylline was not superior to placebo in improving outcomes in patients with acute heart failure enrolled in the PROTECT study, but dyspnoea was improved. "
01/01/2014 - "The prognostic model included 37 clinical characteristics collected at baseline in PROTECT, a study comparing rolofylline and placebo in 2033 patients admitted with acute heart failure. "
06/01/2011 - "Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study."
06/01/2008 - "Results from PROTECT support the use of rolofylline 30 mg/day in acute heart failure, a definitive study is now underway. "
03/01/2012 - "The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. "
|3.||Dyspnea (Shortness of Breath)
01/01/2010 - "Rolofylline 30 mg or matching placebo was given intravenously as a 4-hour continuous infusion on 3 consecutive days and the hospital course was assessed by measurements dyspnea, clinical status, renal function, and subsequent morbidity and mortality in a large population of patients with ADHF with renal impairment."
10/01/2008 - "Compared with placebo, rolofylline produced trends toward greater proportions of patients with marked or moderately improved dyspnea and fewer patients with worsening heart failure or renal function. "
10/07/2010 - "We tested the hypothesis that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea, reduce the risk of worsening renal function, and lead to a more favorable clinical course in patients with acute heart failure. "
09/01/2001 - "Survival time (the time from the commencement of hypoxia until death) was more prolonged with KW-3902 (109.5 +/- 9.1 min) than with saline (37.6 +/- 5.0 min) or vehicle (35.0 +/- 4.2 min) (p < 0.001). "
09/01/2001 - "In protocol II, KW-3902 treatment occurred 2.5, 5, or 7.5 min after hypoxia. "
09/01/2001 - "In protocol I, 5 min after hypoxia, rats were treated with saline, drug vehicle, or KW-3902 (0.1 mg/kg i.v.). "
12/01/1999 - "The administration of KW-3902, however, significantly attenuated hypoxia-induced reduction in renal blood flow. "
01/01/1996 - "KF17837 (0.1 mg/kg, i.v.), but not KW-3902 (0.1 mg/kg, i.v.), inhibited the anemic hypoxia-induced increase in EPO production. "
03/01/2012 - "Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A(1)-receptor antagonists. "
03/01/2012 - "Investigator-reported seizures occurred in 11 (0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). "
10/07/2010 - "Adverse-event rates were similar overall; however, only patients in the rolofylline group had seizures, a known potential adverse effect of A1-receptor antagonists. "
|2.||Purinergic P1 Receptors (Adenosine Receptor)
|4.||Brain Natriuretic Peptide (Natrecor)